- NCIt
- C4573
Loading cancer entity…
Loading cancer entity…
Clinical trials
16 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02978625 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | active not recruiting | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07740993 | A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland Carcinoma | not yet recruiting | Phase 2 | 25 | West China HospitalOTHER | 1 | Aug 3, 2026 |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06715592 | ECT STUDY High-grade or Initially Invasive Vulva - GinOnc-ECT Study | active not recruiting | Phase 2 | 18 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 8, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Aug 13, 2026source: clinicaltrials